<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
Information to be Included in Statements
Filed Pursuant to Rules 13d-1 (b) and (c) and
Amendments Thereto Filed Pursuant to 13d-2(b)
(Amendment No. 2)/1/
Intercardia, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock $.001 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
458 44M 106
- --------------------------------------------------------------------------------
(CUSIP Number)
May 8, 1998
- --------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13 d-1(b)
[ ] Rule 13 d-1(c)
[X] Rule 13 d-1(d)
/1/ The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
13-G
----------- -----------------
CUSIP NO. 458 44M 106 Page 2 of 4 Pages
----------- -----------------
- ------------------------------------------------------------------------------
NAMES OF REPORTING PERSON
1 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Interneuron Pharmaceuticals, Inc.
04-3047911
- ------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
2 (a) [_]
(b) [_]
- ------------------------------------------------------------------------------
SEC USE ONLY
3
- ------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
4
Delaware
- ------------------------------------------------------------------------------
SOLE VOTING POWER
5
NUMBER OF 4,511,084
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 6
0
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
7
REPORTING 4,511,084
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 8
0
- ------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
9
4,511,084
- ------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
10 (SEE INSTRUCTIONS)
[_]
- ------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
11
61.8%
- ------------------------------------------------------------------------------
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
12
CO
- ------------------------------------------------------------------------------
<PAGE>
---------------
PAGE 3 OF 4
---------------
SEC 174__(6-__) * SEE INSTRUCTIONS BEFORE FILLING OUT!
Item 1(a). Name of Issuer:
Intercardia, Inc. (the "Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
3200 East Highway 54
Cape Fear Building, Suite 300
P.O. Box 14287
Research Triangle Park, North Carolina 27709
Item 2(a). Name of Person Filing:
Interneuron Pharmaceuticals, Inc. ("IPI")
Item 2(b). Address of Principal Business Office or if none, Residence:
One Ledgemont Center
99 Hayden Avenue
Lexington, Massachusetts 02173
Item 2(c). Citizenship:
IPI is a corporation organized under the laws of the
State of Delaware.
Item 2(d). Title of Class of Securities:
Common Stock, $.001 par value ("Shares")
Item 2(e). CUSIP Number:
458 44M 106
Item 3. Not Applicable
Item 4. Ownership as of December 31, 1998:
(a) IPI is the beneficial owner of 4,511,084 Shares.
(b) The 4,511,084 Shares beneficially owned by IPI
constitute 61.8% of the Shares of the Issuer outstanding.
(c) (i)-(iv) Reference is made to items 5-8 of the
cover page.
Item 5. Ownership of Five Percent or Less of a Class:
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another
Person:
Not Applicable
Item 7. Identification and Classification of Subsidiary Which
Acquired the Securities:
Not Applicable
Item 8. Identification and Classification of Members of the Group:
Not Applicable
Item 9. Notice of Dissolution of Group:
Not Applicable
Item 10. Certification:
Not Applicable
<PAGE>
Page 4 of 4
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: February 8, 1999 Interneuron Pharmaceuticals, Inc.
Lexington,
Massachusetts
By: /s/ Glenn L. Cooper, M.D.
--------------------------------
Glenn L. Cooper, M.D., President
